SHANGHAI – In what could be called a surprising about-face, Eisai Co. Ltd. has bought itself a small piece of China's generic market with the acquisition of Liaoning Tianyi Biological Pharmaceutical Co. Ltd., for $78.2 million. Eisai's execs said they are hoping to take advantage of a segment they believe will see robust growth in the coming years in China: high-quality generic drugs.